Trabectedin and Immune Checkpoint Inhibitors: A Blissful Combination or Another Failure in Soft Tissue Sarcomas?
Immunotherapy · 2023
DOI: 10.2217/imt-2022-0157 ↗Kurz gefasst
Editorial in der Zeitschrift Immunotherapy, 2023. Verfasst von Tarek Assi und 1 weiteren Autor:innen. Beteiligte Einrichtung: Division of International Patients Care, Gustave Roussy Cancer Campus, Villejuif, France. Hauptthemen laut MEDLINE: Immune Checkpoint Inhibitors, Sarcoma. Die Arbeit nennt 20 Literaturangaben.
Abstract (Originalsprache)
Soft tissue sarcomas (STS), which constitute around 1% of all neoplasms, are composed of a multitude of distinct mesenchymal tumors with different clinical and genetic features [1]. Advanced STS re...
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of International Patients Care, Gustave Roussy Cancer Campus, Villejuif, France.
ORCID-Profile: Tarek Assi
Zitieren
APA
Assi, T., & Cesne, A. L. (2023). Trabectedin and Immune Checkpoint Inhibitors: A Blissful Combination or Another Failure in Soft Tissue Sarcomas?. Immunotherapy. https://doi.org/10.2217/imt-2022-0157
Vancouver
Assi T, Cesne AL. Trabectedin and Immune Checkpoint Inhibitors: A Blissful Combination or Another Failure in Soft Tissue Sarcomas?. Immunotherapy. 2023. doi:10.2217/imt-2022-0157
BibTeX
@article{Assi2023,
author = {Assi, Tarek and Cesne, Axel Le},
title = {Trabectedin and Immune Checkpoint Inhibitors: A Blissful Combination or Another Failure in Soft Tissue Sarcomas?},
journal = {Immunotherapy},
year = {2023},
doi = {10.2217/imt-2022-0157}
}
EUVIMED